Bruce Carter, Ph.D.

Bruce is an affiliate Professor in the Department of Biotechnology at the University of Washington, Seattle—a position he has held since 1986. He currently serves on the board of directors of Mirati and Enanta Pharmaceuticals, publicly held biopharmaceutical companies, and Dr. Reddy’s Laboratories, a publicly held pharmaceutical company based in India. Bruce also serves as Chairman of the board at the TB Alliance.

Prior to his current appointment, Bruce served as Executive Chairman of the board at Immune Design Corp. from 2009 to 2011, later serving as Chairman of the board until 2012 and as a member of the board until 2015. Between 1986 and 1994, Bruce served as Vice President of Research and Development as well as Chief Executive Officer at ZymoGenetics, Inc. In 1988, Novo Nordisk A/S acquired ZymoGenetics, leading to Bruce appointment as Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk in 1994. In 2000, Bruce led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk. As CEO, he was instrumental in transforming ZymoGenetics from the research arm of a European biopharmaceutical company to a company that developed and commercialized Recothrom.* Bruce also held various positions of increasing responsibility at G.D. Searle & Co., Ltd. from 1982 to 1986 and was a lecturer in genetics at Trinity College, University of Dublin from 1975 to 1982.

He received a Ph.D. in Microbiology from Queen Elizabeth College, University of London, and a B.Sc. with Honors in Botany from the University of Nottingham, England.

* Trademarks are property of their respective owners.

About Cookies on This Site

This website uses cookies. Essential and functional cookies are necessary for the proper functioning of this website and cannot be refused. Other cookies are used for statistical purposes and will only be placed if you agree to their placement. For further details on cookies, how we use cookies and how to modify your choices regarding cookies, please read our Cookies Policy.